Jefferies Financial Group Reaffirms “Buy” Rating for Oxford Biomedica (LON:OXB)

Oxford Biomedica (LON:OXB)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Financial Group in a report released on Monday, MarketBeat reports. They currently have a GBX 827 target price on the biopharmaceutical company’s stock. Jefferies Financial Group‘s price objective indicates a potential upside of 57.52% from the company’s current price.

OXB has been the subject of a number of other research reports. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 818.

Oxford Biomedica Price Performance

OXB traded up GBX 11 on Monday, hitting GBX 525. 7,696,761 shares of the company were exchanged, compared to its average volume of 1,080,181. The firm has a market capitalization of £635.50 million, a P/E ratio of -16.43 and a beta of 1.11. The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21. The business’s fifty day moving average is GBX 495.12 and its 200 day moving average is GBX 612.23. Oxford Biomedica has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 952.

Oxford Biomedica (LON:OXB) last released its quarterly earnings data on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. As a group, sell-side analysts anticipate that Oxford Biomedica will post -31.08 EPS for the current year.

Insider Buying and Selling at Oxford Biomedica

In related news, insider Roch Doliveux acquired 20,250 shares of Oxford Biomedica stock in a transaction dated Wednesday, September 23rd. The shares were acquired at an average cost of GBX 505 per share, for a total transaction of £102,262.50. 25.83% of the stock is currently owned by company insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.